Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (61-70 of 335) with videos related to

Pageof 34
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 12, 2024
Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinomaSara Elena Rebuzzi, Giuseppe Fornarini, Giuseppe Luigi Banna, et al.
Drugs in R&D|September 13, 2017
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective StudySebastiano Buti, Maddalena Donini, Melissa Bersanelli, et al.
Tumori|March 29, 2014
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case reportPaola Bordi, Marcello Tiseo, Beatrice Bortesi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 21, 2020
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysisSebastiano Buti, Fausto Petrelli, Antonio Ghidini, et al.
Expert Review of Anticancer Therapy|October 31, 2006
Immunotherapy options in metastatic renal cell cancer: where we are and where we are goingRodolfo Passalacqua, Sebastiano Buti, Gianluca Tomasello, et al.
Journal of Cancer Research and Therapeutics|February 17, 2016
Very late recurrence of an apparently benign pheochromocytomaElena Thai, Letizia Gnetti, Annalisa Gilli, et al.
Immunotherapy|November 22, 2021
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysisSebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, et al.
Expert Review of Molecular Diagnostics|October 15, 2019
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic reviewSara Elena Rebuzzi, Fabiana Perrone, Melissa Bersanelli, et al.
Tumori|April 13, 2012
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinomaSebastiano Buti, Rodrigo Kraft Rovere, Maddalena Donini, et al.
Cancers|October 2, 2014
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapyMelissa Bersanelli, Sebastiano Buti, Roberta Camisa, et al.
Pageof 34

Showing results (61-70 of 335) with videos related to

Sort By:
Pageof 34
European Journal of Cancer (Oxford, England : 1990)|May 12, 2024
Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinomaSara Elena Rebuzzi, Giuseppe Fornarini, Giuseppe Luigi Banna, et al.
Drugs in R&D|September 13, 2017
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective StudySebastiano Buti, Maddalena Donini, Melissa Bersanelli, et al.
Tumori|March 29, 2014
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case reportPaola Bordi, Marcello Tiseo, Beatrice Bortesi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 21, 2020
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysisSebastiano Buti, Fausto Petrelli, Antonio Ghidini, et al.
Expert Review of Anticancer Therapy|October 31, 2006
Immunotherapy options in metastatic renal cell cancer: where we are and where we are goingRodolfo Passalacqua, Sebastiano Buti, Gianluca Tomasello, et al.
Journal of Cancer Research and Therapeutics|February 17, 2016
Very late recurrence of an apparently benign pheochromocytomaElena Thai, Letizia Gnetti, Annalisa Gilli, et al.
Immunotherapy|November 22, 2021
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysisSebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, et al.
Expert Review of Molecular Diagnostics|October 15, 2019
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic reviewSara Elena Rebuzzi, Fabiana Perrone, Melissa Bersanelli, et al.
Tumori|April 13, 2012
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinomaSebastiano Buti, Rodrigo Kraft Rovere, Maddalena Donini, et al.
Cancers|October 2, 2014
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapyMelissa Bersanelli, Sebastiano Buti, Roberta Camisa, et al.
Pageof 34